Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
禮來買下Morphic Holding Inc的股票，每股價格爲57美元，總額約爲32億美元。
Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn's disease.
領先資產MORF-057是一種小分子抑制劑，目前正在進行潰瘍性結腸炎的20億期臨床試驗，預計於2025年上半年揭曉結果。它最近啓動了一項克羅恩病的2期研究。
Also Read: Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst.
也閱讀：艾默生研究的抗澱粉樣抗體療法廣泛適用的標籤反映了監管機構對抗澱粉樣蛋白的信懇智能的信心：分析師。
Goldman Sachs writes that α4β7 is a clinically validated target in inflammatory bowel disease (IBD), as it notes Takeda Pharmaceutical Company Ltd's (NYSE:TAK) Entyvio generated $5.3 billion sales fiscal year 2023 in UC and Crohn's disease.
高盛表示，α4β7在炎症性腸病(IBD)中是一種臨床上驗證的靶點，因爲它指出武田製藥有限公司（紐交所:TAK）的安泰唑在2023財年中在UC和克羅恩病中產生了53億的銷售額。
The analyst notes the proposed deal has strategic merit and would present a potentially helpful step toward strengthening the company's pipeline portfolio in Immunology.
分析師指出，建議的交易具有戰略優勢，並將是加強公司免疫學管線組合的潛在有益步驟。
Although investors are primarily focused on the obesity franchise's performance and outlook, deals like these are crucial for strengthening the company's diverse therapeutic areas, such as Immunology.
儘管投資者主要關注肥胖治療應用的表現和前景，但此類交易對於加強公司多樣化治療領域（如免疫學）至關重要。
Despite receiving less attention from investors, Immunology remains an important development area for the company.
儘管受到投資者關注較少，但免疫學仍是公司的一個重要發展領域。
Last year, Eli Lilly acquired DICE Therapeutics, a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral therapeutic candidates for immunology indications for $48 per share.
去年，艾默生以48美元的價格收購了DICE Therapeutics，該生物製藥公司利用其專有的DELSCAPE技術平台開發口服治療候選藥物，用於免疫學適應症。
Goldman Sachs reiterates the Neutral rating with a price target of $793.
高盛重申中立評級，價格目標爲793美元。
Price Action: LLY shares are up 0.72% at $924.64 at last check Tuesday.
股價表現：截至本週二最後一次檢查，LLY股價上漲0.72％，爲924.64美元。
- Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows.
- 研究表明，艾默生的蒙賈羅在減肥效果方面超越了諾和諾德的奧澤匹克。